Objective To investigate the concentration of S-100 protein presenting in cerebrospinal fluid (CSF) and blood serum in patients with Guillain-Barr? syndrome (GBS), and discuss the value of assessment in measuring S-100 protein level to Schwann′s cell insult. Methods S-100 beta protein was measured dynamically by ELISA in CSF and blood serum from 50 patients with GBS and 22 referencesThe patients were divided into two categories by disease severity: the severe group and the mild groupMeanwhile, CSF cytology was also detected. Results (1) The level of CSF S-100 beta protein in both severe and mild groups were higher than that of the control group (P0.05)(2) The percentage of CSF monocyte in severe group was higher than that of the mild and the control groups(P0.05)(3) There was a dynamic change of CSF S-100 beta protein level in GBS patients correlated with the percentage of CSF monocyte and the severity of disease. Conclusions CSF and blood serum S-100 beta protein level in patients with GBS may be related to the severity of the disease.

In order to explore the value of assessment in measuring S-100 beta protein (S-100B protein) and neuron-specific enolase (NSE) present in cerebrospinal fluid (CSF) from patients with brain insult in central nervous system infections, S-100B protein and NSE in CSF were measured dynamically by ELISA in 42 patients with Herpes Simplex Encephalitis (USE), 19 patients with purulent meningitis, 17 patients with cryptococcus meningitis and 22 unrelated control patients. It was found that the levels of CSF S-100B protein in all the three groups were higher than that of the control group (P0. 05). There were dynamic changes of CSF S-100B protein and NSE concentrations in all three groups correlating with the severity of disease. It is suggested that elevated concentrations of S-100B protein and NSE in CSF related to the damage of glia and neurons could be used as CSF markers of brain insult in patients with central nervous system infections.

AIM: To study the efficacy and safety of dispersible formulation of levodopa-benserazide on the parkinson disease.　METHODS: The multicenter, open-label, self-controlled trial was conducted at 23 hospitals in 15 cities. Two hundred and four patients with idiopathic parkinson who had received standard levodopa-benserazide previously participated in this study. Dispersible levodopa-benserazide instead of standard levodopa-benserazide for 8 wk as a course. The Webster rating scale and patient diary were applied to assess the efficacy and safety of dispersible levodopa-benserazide.　RESULTS： The medication with dispersible levodopa-benserazide increased “on” time by 47 min, decreased “off” time by 11 min, and speeded the onset of “on” time by 37 min. The Webster score was improved by 25 %. Statistical significant difference was calculated (P<0.01). Slight and few adverse reactions were found.　CONCLUSION: Dispersible formulation of levodopa-benserazide is a powerful anti-parkinsonian drug characterized by oral easy use and rapid reach to therapeutic action after ingestion. This drug is particularly used in the parkinsonian patients with morning akinesia, delayed onset of “on” time, afternoon “off” status and dysphagia.